We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

CAROLINA LIQUID CHEMISTRIES

Carolina Liquid Chemistries offers a complete line of clinical chemistry analyzers and reagents for use on common pla... read more Featured Products: More products

Download Mobile App




Automated Glycated Hemoglobin Assay Now Certified by US Glycohemoglobin Standardization Program

By LabMedica International staff writers
Posted on 24 Jul 2014
Print article
Image: The CLC720 chemistry analyzer (Photo courtesy of the Carolina Liquid Chemistries Corporation).
Image: The CLC720 chemistry analyzer (Photo courtesy of the Carolina Liquid Chemistries Corporation).
An assay for the measurement of glycated hemoglobin (HbA1c) designed for use on a new-generation automated chemistry analyzer was recently certified by the [US] National Glycohemoglobin Standardization Program (NGSP).

HbA1c is a derivative of hemoglobin that is formed nonenzymically by reaction at the N terminus of the protein molecule with glucose. In the normal adult human such derivatives constitute a few percent of the total erythrocyte hemoglobin, the most abundant being hemoglobin A1c, which increases several fold in concentration in diabetes mellitus, and is assayed to monitor control of diabetes. Once a hemoglobin molecule is glycated, it remains that way. A buildup of glycated hemoglobin within the red cell, therefore, reflects the average level of glucose to which the cell has been exposed during its life-cycle. Measuring glycated hemoglobin assesses the effectiveness of therapy by monitoring long-term serum glucose regulation. The HbA1c level is proportional to average blood glucose concentration over the previous four weeks to three months.

In the United States, HbA1c testing laboratories are certified by the National Glycohemoglobin Standardization Program (NGSP) to standardize them against the results of the 1993 Diabetes Control and Complications Trial (DCCT). This landmark study showed that the risk for development and progression of the chronic complications of diabetes was closely related to the degree of glycemic control, as measured by HbA1c. The DCCT also provided a large body of data relating HbA1c values to mean blood glucose.

Carolina Liquid Chemistries Corporation (Winston-Salem, NC, USA) recently announced today that its new Hemoglobin A1c test (HbA1c-direct), designed for use on the CLC720 chemistry analyzer had been certified by the NGSP.

“There are other HbA1c tests on the market,” said Patricia Shugart, chief operating officer at Carolina Liquid Chemistries Corporation, “but our HbA1c-direct is special in two ways. First, it’s a direct test, meaning there is no manual sample pretreatment. Second, it is categorized as moderately complex, which avoids the extra cost of a high complexity lab.”

The speed and ease of HbA1c-direct is made possible by the enhanced capabilities of the CLC720 chemistry analyzer, which, unlike most analyzers in its class, automates the lysing step that would otherwise have to be performed manually.

“Our test correlates to the NGSP certified tests used in large-scale diabetes studies,” said Patricia Shugart. “Physicians can now relate their HbA1c-direct results to these studies, providing more relevance.”

Related Links:
Carolina Liquid Chemistries Corporation



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: The new blood test identifies key biomarkers of osteoarthritis (Photo courtesy of Shutterstock)

Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays

Osteoarthritis (OA) is the most prevalent form of arthritis, impacting millions worldwide and resulting in significant economic and social costs. Although no cure exists currently, the effectiveness of... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The Sampler device could revolutionize sample collection for diagnostic tests (Photo courtesy of ReadyGo Diagnostics)

First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests

The COVID pandemic has dramatically reshaped the perception of diagnostics. Post the pandemic, a groundbreaking device that combines sample collection and processing into a single, easy-to-use disposable... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.